Alnylam Pharmaceuticals, Inc. (ALNY)

397.46 -15.17 (-3.68%) USD  |  NASDAQ  |  Dec 12, 10:54
More

Alnylam Pharmaceuticals Revenue Estimates for Current Fiscal Year

Revenue Estimates for Current Fiscal Year Chart

View Revenue Estimates for Current Fiscal Year for ALNY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue Estimates for Current Fiscal Year Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Revenue Estimates for Current Fiscal Year Range, Past 5 Years

View Revenue Estimates for Current Fiscal Year Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue Estimates for Current Fiscal Year Benchmarks

View Revenue Estimates for Current Fiscal Year Benchmarks
Start Trial
Pfizer Inc. Upgrade
Glaukos Corp. Upgrade
Bristol Myers Squibb Co. Upgrade
BridgeBio Pharma, Inc. Upgrade
Vertex Pharmaceuticals, Inc. Upgrade

Revenue Estimates for Current Fiscal Year Related Metrics

Revenue Estimates for Current Quarter Upgrade
Revenue Estimates for Next Quarter Upgrade
Revenue Estimates for Next Fiscal Year Upgrade
EPS Estimates for Current Quarter Upgrade
EPS Estimates for Next Quarter Upgrade
EPS Estimates for Current Fiscal Year Upgrade
EPS Estimates for Next Fiscal Year Upgrade